Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT NASDAQ:FNCH NASDAQ:ITOS NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$6.00+4.2%$5.41$4.59▼$14.36$11.52M0.9138,524 shs9,994 shsFNCHFinch Therapeutics Group$12.05$12.39$10.15▼$15.85$19.35M1.172,274 shs68 shsITOSiTeos Therapeutics$10.15$10.14$4.80▼$17.63$448.73M1.311.51 million shsN/APHARPharming Group$13.60-8.2%$14.27$7.31▼$17.08$931.80M0.0412,494 shs12,336 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics0.00%+4.46%+8.50%-5.06%-53.84%FNCHFinch Therapeutics Group0.00%-0.41%-4.21%-3.98%+0.42%ITOSiTeos Therapeutics0.00%0.00%0.00%-0.20%+14.69%PHARPharming Group0.00%-2.86%-8.11%+32.55%+51.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$6.00+4.2%$5.41$4.59▼$14.36$11.52M0.9138,524 shs9,994 shsFNCHFinch Therapeutics Group$12.05$12.39$10.15▼$15.85$19.35M1.172,274 shs68 shsITOSiTeos Therapeutics$10.15$10.14$4.80▼$17.63$448.73M1.311.51 million shsN/APHARPharming Group$13.60-8.2%$14.27$7.31▼$17.08$931.80M0.0412,494 shs12,336 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics0.00%+4.46%+8.50%-5.06%-53.84%FNCHFinch Therapeutics Group0.00%-0.41%-4.21%-3.98%+0.42%ITOSiTeos Therapeutics0.00%0.00%0.00%-0.20%+14.69%PHARPharming Group0.00%-2.86%-8.11%+32.55%+51.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.60Moderate Buy$34.00466.67% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AITOSiTeos Therapeutics 2.14Hold$15.5052.71% UpsidePHARPharming Group 2.60Moderate Buy$30.00120.59% UpsideCurrent Analyst Ratings BreakdownLatest BOLT, FNCH, OXB, PHAR, and ITOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025PHARPharming GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)10/24/2025BOLTBolt BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/22/2025BOLTBolt BiotherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/20/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$7.0010/20/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.0010/8/2025BOLTBolt BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PHARPharming GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/30/2025PHARPharming GroupZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/27/2025BOLTBolt BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PHARPharming GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)8/15/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.50N/AN/A$29.89 per share0.20FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91PHARPharming Group$297.20M3.14$0.07 per share183.47$3.25 per share4.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$26.66N/AN/AN/AN/A-91.67%-53.19%11/11/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%11/11/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A453.33N/A-2.19%-3.31%-1.78%11/6/2025 (Estimated)Latest BOLT, FNCH, OXB, PHAR, and ITOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025BOLTBolt Biotherapeutics-$5.08N/AN/AN/AN/AN/A11/6/2025Q3 2025PHARPharming Group$0.05N/AN/AN/AN/AN/A8/14/2025Q2 2025BOLTBolt Biotherapeutics-$6.40-$4.46+$1.94-$4.46$0.82 million$1.80 million8/6/2025Q2 2025ITOSiTeos Therapeutics-$1.12-$1.51-$0.39-$1.81N/AN/A7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.563.113.11FNCHFinch Therapeutics GroupN/A3.873.87ITOSiTeos TherapeuticsN/A7.537.53PHARPharming Group0.382.792.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%FNCHFinch Therapeutics Group21.77%ITOSiTeos Therapeutics97.16%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%FNCHFinch Therapeutics Group44.90%ITOSiTeos Therapeutics14.20%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.80 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataITOSiTeos Therapeutics9044.21 million37.93 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionableBOLT, FNCH, OXB, PHAR, and ITOS HeadlinesRecent News About These CompaniesPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's WhyOctober 25 at 1:50 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Up 9.5% - What's Next?October 24 at 2:20 PM | marketbeat.comPharming Group to report third quarter 2025 financial results and provide business update on November 6October 23 at 8:09 AM | finance.yahoo.comFDA accepts supplemental new drug application for leniolisib for children with APDSOctober 20, 2025 | healio.comHPharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolioOctober 20, 2025 | markets.businessinsider.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 71.8% in SeptemberOctober 18, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What HappenedOctober 15, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Should You Buy?October 13, 2025 | marketbeat.comPharming Group (ENXTAM:PHARM): Assessing Valuation Following Major Cost-Cutting and Restructuring MoveOctober 10, 2025 | finance.yahoo.comPharming Group (NASDAQ:PHAR) Earns "Sell (D+)" Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comPharming Group Announces Restructuring to Cut Costs and Boost GrowthOctober 8, 2025 | msn.comPharming Group (NASDAQ:PHAR) Shares Gap Down - What's Next?October 8, 2025 | marketbeat.comPharming announces 20% net reduction in non-commercial, non-medical headcountOctober 7, 2025 | msn.comPharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Should You Buy?October 7, 2025 | marketbeat.comShort Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 64.2%October 6, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Down 4.6% - What's Next?October 6, 2025 | marketbeat.comPharming Group provides update on previously announced G&A expense reduction planOctober 6, 2025 | markets.businessinsider.comFDA accepts supplemental New Drug Application for Pharming’s paediatric immunodeficiency therapyOctober 3, 2025 | pmlive.comPPharming Group (NASDAQ:PHAR) Cut to "Hold" at Zacks ResearchOctober 2, 2025 | marketbeat.comPharming Group’s Leniolisib Receives FDA Priority Review for Pediatric APDS TreatmentOctober 1, 2025 | msn.comPharming Group (NASDAQ:PHAR) Stock Price Up 7% - Still a Buy?October 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTrumpRx Brings Pfizer Into the Green—Is It a Buy?By Jordan Chussler | October 7, 2025Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma GiantsBy Gabriel Osorio-Mazilli | October 6, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 20252 Reasons Absci Could Be the Future of AI Biotech, and 1 RiskBy Nathan Reiff | October 13, 20253 Lesser-Known Healthcare Names With Major Upside in StoreBy Nathan Reiff | October 2, 2025BOLT, FNCH, OXB, PHAR, and ITOS Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$6.00 +0.24 (+4.17%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$6.00 +0.00 (+0.08%) As of 10/24/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Finch Therapeutics Group NASDAQ:FNCH$12.05 0.00 (0.00%) As of 10/24/2025Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.iTeos Therapeutics NASDAQ:ITOSiTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Pharming Group NASDAQ:PHAR$13.60 -1.21 (-8.17%) Closing price 10/24/2025 03:51 PM EasternExtended Trading$13.52 -0.07 (-0.55%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
